Enclosed please find Unaudited Standalone and Consolidated Financial Results for the Quarter and nine months ended December 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GKB Ophthalmics reported consolidated revenue of Rs. 5,679.35 lakhs for Q3 FY26, more than doubling from Rs. 2,580.41 lakhs in Q3 FY25. For the nine months ended December 31, 2025, consolidated revenue rose about 53% to Rs. 11,927.08 lakhs from Rs. 7,796.47 lakhs a year ago. The company swung to a consolidated profit after tax of Rs. 190.77 lakhs in 9M FY26 from a loss of Rs. 295.04 lakhs in 9M FY25, with EPS of Rs. 2.03 versus Rs. (6.94). On a standalone basis, however, revenue declined nearly 21% to Rs. 1,924.23 lakhs and the company stayed in loss at Rs. 168.48 lakhs for the nine-month period. The subsidiary GSV Ophthalmics is being voluntarily wound up, with Rs. 7.95 crore of the Rs. 11.70 crore investment already received.
Consolidated numbers show a sharp turnaround driven by subsidiaries, while the standalone lens business remains weak and loss-making. Investors should note the divergence between consolidated growth and standalone stress, and watch the orderly wind-up of GSV and standalone cost rationalisation as key near-term triggers.